{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:56:16Z","timestamp":1781798176436,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Orthop Trauma Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The NarxCare Overdose Risk Score (ORS) is a weighted measure of patient-specific prescription drug use. In patients undergoing primary total hip arthroplasty (THA), this study aimed to evaluate (1) the trend of the ORS from preoperative to 1-year postoperatively, and (2) the association of preoperative ORS with achievement of clinically meaningful improvements in patient reported outcome measures (PROMs), and satisfaction at 1-year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients who underwent primary unilateral elective THA at a USA tertiary healthcare system from January 2016-December 2022 were eligible. Patients with incomplete PROMs or missing baseline NarxCare ORS were excluded, leading to the inclusion of 5,424 patients. Multivariable regression models were used to assess the association between ORS and 1-year PROMs, including achievement of the minimum clinically important difference (MCID) and Patient Acceptable Symptom State (PASS) for the Hip Disability and Osteoarthritis Outcome Score (HOOS) subdomain scores, as well as satisfaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Preoperatively, 46.1% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092501) had a NarxCare ORS of 0, 24.6% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091336) had scores between 100 and 199, and 16.2% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009876) in the 200\u2013299 range. After adjusting for confounding variables, a preoperative ORS of 100\u2013199 was associated with failure to achieve MCID in HOOS Pain (OR 1.91;CI 1.32\u20132.77;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), and HOOS JR (OR 1.54;1.10\u20132.15;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012). Preoperative ORS of 100\u2013199 was also associated with failure to reach PASS threshold in HOOS Pain (OR 1.45;1.23\u20131.71;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), PS (OR 1.47;1.22\u20131.75;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and JR (OR 1.26;1.08\u20131.49;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), with the odds of failure continually increasing as the ORS increases. Patients with a preoperative ORS of 100\u2013199 were 58% more likely to be dissatisfied at 1-year (OR 1.58;1.26\u20131.99;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) compared to prescription drug use na\u00efve patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Increasing preoperative NarxCare ORS, a measure of prescription drug use, is inversely associated with patient perceived improvement after THA. An ORS of just 100 may significantly decrease the chances of clinically meaningful improvements in hip pain and function, as well as satisfaction at 1-year. A multidisciplinary approach is warranted to mitigate the detrimental effects of sedatives, opioids, or stimulant drug use and surgeons may use this easily accessible score to guide a patient centered discussion regarding postoperative improvements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of evidence<\/jats:title>\n                    <jats:p>III.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00402-026-06372-7","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:33:59Z","timestamp":1781796839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative NarxCare overdose risk scores greater than 100 are associated with worse PROMs improvements and dissatisfaction after primary THA"],"prefix":"10.1007","volume":"146","author":[{"given":"Shujaa T.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed K.","family":"Emara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlok V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled A.","family":"Elmenawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Ibaseta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Pasqualini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Cleveland Clinic Adult Reconstruction Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas S.","family":"Piuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"6372_CR1","unstructured":"Prescription Drug Abuse Statistics [Internet]. National Center for Drug Abuse Statistics. https:\/\/drugabusestatistics.org\/prescription-drug-abuse-statistics\/"},{"issue":"4","key":"6372_CR2","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.1097\/SLA.0000000000005767","volume":"278","author":"AC Fernandez","year":"2023","unstructured":"Fernandez AC, Waljee JF, Gunaseelan V, Brummett CM, Englesbe MJ, Bicket MC (2023) Prevalence of Unhealthy Substance Use and Associated Characteristics Among Patients Presenting for Surgery. Ann Surg 278(4):e740\u2013e744. https:\/\/doi.org\/10.1097\/SLA.0000000000005767","journal-title":"Ann Surg"},{"key":"6372_CR3","doi-asserted-by":"publisher","unstructured":"Pasqualini I, Rull\u00e1n PJ, Deren M, Krebs VE, Molloy RM, Nystrom LM et al (2023) Team Approach: Use of Opioids in Orthopaedic Practice. JBJS Rev 11(3). https:\/\/doi.org\/10.2106\/JBJS.RVW.22.00209","DOI":"10.2106\/JBJS.RVW.22.00209"},{"issue":"1","key":"6372_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/BRS.0000000000004459","volume":"48","author":"AK Emara","year":"2023","unstructured":"Emara AK, Sultan A, Grits D, Savage J, Piuzzi NS, Pelle DW (2023) Opioid and Sedative NarxCare Scores Greater Than 300 Are Associated With Adverse Outcomes After Nonemergent Spine Surgery. Spine (Phila Pa 1976) 48(1):29\u201338. https:\/\/doi.org\/10.1097\/BRS.0000000000004459","journal-title":"Spine (Phila Pa 1976)"},{"issue":"24","key":"6372_CR5","doi-asserted-by":"publisher","first-page":"00530","DOI":"10.1016\/j.arth.2024.05.058","volume":"S0883\u20135403","author":"ST Khan","year":"2024","unstructured":"Khan ST, Pasqualini I, Rull\u00e1n PJ, Tidd J, Jin Y, Klika AK et al (2024) Predictive Modeling of Medical- and Orthopaedic-Related 90-Day Readmissions Following Primary Total Hip Arthroplasty. J Arthroplasty S0883\u20135403(24):00530\u201300538. https:\/\/doi.org\/10.1016\/j.arth.2024.05.058","journal-title":"J Arthroplasty"},{"issue":"6S","key":"6372_CR6","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.1016\/j.arth.2020.02.014","volume":"35","author":"N Sodhi","year":"2020","unstructured":"Sodhi N, Anis HK, Acu\u00f1a AJ, Vakharia RM, Piuzzi NS, Higuera CA et al (2020) The Effects of Opioid Use on Thromboembolic Complications, Readmission Rates, and 90-Day Episode of Care Costs After Total Hip Arthroplasty. J Arthroplasty 35(6S):S237\u2013S240. https:\/\/doi.org\/10.1016\/j.arth.2020.02.014","journal-title":"J Arthroplasty"},{"issue":"2","key":"6372_CR7","doi-asserted-by":"publisher","first-page":"e061","DOI":"10.1097\/AS9.0000000000000061","volume":"2","author":"AK Emara","year":"2021","unstructured":"Emara AK, Klika AK, Piuzzi NS (2021) A Call for Improved Screening of Preoperative Prescription Drug Abuse: A Scalar Assessment Not Limited to Opioids. Ann Surg Open 2(2):e061. https:\/\/doi.org\/10.1097\/AS9.0000000000000061","journal-title":"Ann Surg Open"},{"key":"6372_CR8","unstructured":"Appriss Health About NarxCare For Patients and Their Families [Internet]. [cited 2024 Dec 12]. https:\/\/www.floridahealth.gov\/statistics-and-data\/e-forcse\/narxcare-patient-information-sheet.pdf"},{"key":"6372_CR9","unstructured":"Bamboo Helath. NarxCare\u00ae [Internet]. [cited 2024 Dec 12]. https:\/\/bamboohealth.com\/solutions\/narxcare\/"},{"issue":"9","key":"6372_CR10","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1016\/j.arth.2018.03.066","volume":"33","author":"KA Cryar","year":"2018","unstructured":"Cryar KA, Hereford T, Edwards PK, Siegel E, Barnes CL, Mears SC (2018) Preoperative Smoking and Narcotic, Benzodiazepine, and Tramadol Use are Risk Factors for Narcotic Use After Hip and Knee Arthroplasty. J Arthroplasty 33(9):2774\u20132779. https:\/\/doi.org\/10.1016\/j.arth.2018.03.066","journal-title":"J Arthroplasty"},{"issue":"22","key":"6372_CR11","doi-asserted-by":"publisher","first-page":"e1016","DOI":"10.5435\/JAAOS-D-18-00658","volume":"27","author":"BE Bonner","year":"2019","unstructured":"Bonner BE, Castillo TN, Fitz DW, Zhao JZ, Klemt C, Kwon YM (2019) Preoperative Opioid Use Negatively Affects Patient-reported Outcomes After Primary Total Hip Arthroplasty. J Am Acad Orthop Surg 27(22):e1016\u2013e1020. https:\/\/doi.org\/10.5435\/JAAOS-D-18-00658","journal-title":"J Am Acad Orthop Surg"},{"issue":"9","key":"6372_CR12","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1097\/CORR.0000000000001745","volume":"479","author":"AK Emara","year":"2021","unstructured":"Emara AK, Grits D, Klika AK, Molloy RM, Krebs VE, Barsoum WK et al (2021) NarxCare Scores Greater Than 300 Are Associated with Adverse Outcomes After Primary THA. Clin Orthop Relat Res 479(9):1957\u20131967. https:\/\/doi.org\/10.1097\/CORR.0000000000001745","journal-title":"Clin Orthop Relat Res"},{"key":"6372_CR13","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2106\/JBJS.23.01013","volume":"106","author":"I Pasqualini","year":"2024","unstructured":"Pasqualini I, Piuzzi NS (2024) New CMS Policy on the Mandatory Collection of Patient-Reported Outcome Measures for Total Hip and Knee Arthroplasty by 2027: What Orthopaedic Surgeons Should Know. J Bone Joint Surg Am 106:1233\u20131241. https:\/\/doi.org\/10.2106\/JBJS.23.01013","journal-title":"J Bone Joint Surg Am"},{"key":"6372_CR14","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.18.00767","author":"OME Cleveland Clinic Orthopaedics","year":"2019","unstructured":"OME Cleveland Clinic Orthopaedics (2019) Implementing a Scientifically Valid, Cost-Effective, and Scalable Data Collection System at Point of Care: The Cleveland Clinic OME Cohort. J Bone Joint Surg Am 101(5):458\u2013464. https:\/\/doi.org\/10.2106\/JBJS.18.00767"},{"key":"6372_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2018.07.011","author":"GL Curtis","year":"2018","unstructured":"Curtis GL, Tariq MB, Brigati DP, Faour M, Higuera CA, Cleveland Clinic Orthopaedic Arthroplasty Group (2018) Validation of a Novel Surgical Data Capturing System Following Total Hip Arthroplasty. J Arthroplasty 33(11):3479\u20133483. https:\/\/doi.org\/10.1016\/j.arth.2018.07.011."},{"issue":"10","key":"6372_CR16","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.arth.2022.04.041","volume":"37","author":"D Grits","year":"2022","unstructured":"Grits D, Emara AK, Klika AK, Murray TG, McLaughlin JP, Piuzzi NS (2022) Neighborhood Socioeconomic Disadvantage Associated With Increased Healthcare Utilization After Total Hip Arthroplasty. J Arthroplasty 37(10):1980\u20131986e2. https:\/\/doi.org\/10.1016\/j.arth.2022.04.041","journal-title":"J Arthroplasty"},{"issue":"7S","key":"6372_CR17","doi-asserted-by":"publisher","first-page":"S498","DOI":"10.1016\/j.arth.2022.02.042","volume":"37","author":"MN Orr","year":"2022","unstructured":"Orr MN, Klika AK, Emara AK, Cleveland Clinic Arthroplasty Group, Piuzzi NS (2022) Dissatisfaction After Total Hip Arthroplasty Associated With Preoperative Patient-Reported Outcome Phenotypes. J Arthroplasty 37(7S):S498\u2013509. https:\/\/doi.org\/10.1016\/j.arth.2022.02.042","journal-title":"J Arthroplasty"},{"issue":"6","key":"6372_CR18","doi-asserted-by":"publisher","first-page":"e2113977","DOI":"10.1001\/jamanetworkopen.2021.13977","volume":"4","author":"AK Emara","year":"2021","unstructured":"Emara AK, Santana D, Grits D, Klika AK, Krebs VE, Molloy RM et al (2021) Exploration of Overdose Risk Score and Postoperative Complications and Health Care Use After Total Knee Arthroplasty. JAMA Netw Open 4(6):e2113977. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.13977","journal-title":"JAMA Netw Open"},{"issue":"22","key":"6372_CR19","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.2106\/JBJS.21.00030","volume":"103","author":"MN Orr","year":"2021","unstructured":"Orr MN, Klika AK, Gagnier JJ, Bhandari M, Piuzzi NS (2021) A Call for a Standardized Approach to Reporting Patient-Reported Outcome Measures: Clinical Relevance Ratio. J Bone Joint Surg 103(22):e91. https:\/\/doi.org\/10.2106\/JBJS.21.00030","journal-title":"J Bone Joint Surg"},{"issue":"3","key":"6372_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.cger.2012.05.007","volume":"28","author":"NJ Collins","year":"2012","unstructured":"Collins NJ, Roos EM (2012) Patient-reported outcomes for total hip and knee arthroplasty: commonly used instruments and attributes of a good measure. Clin Geriatr Med 28(3):367\u2013394. https:\/\/doi.org\/10.1016\/j.cger.2012.05.007","journal-title":"Clin Geriatr Med"},{"issue":"5","key":"6372_CR21","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.arth.2019.12.038","volume":"35","author":"SM Goodman","year":"2020","unstructured":"Goodman SM, Mehta BY, Mandl LA, Szymonifka JD, Finik J, Figgie MP et al (2020) Validation of the Hip Disability and Osteoarthritis Outcome Score and Knee Injury and Osteoarthritis Outcome Score Pain and Function Subscales for Use in Total Hip Replacement and Total Knee Replacement Clinical Trials. J Arthroplasty 35(5):1200\u20131207e4. https:\/\/doi.org\/10.1016\/j.arth.2019.12.038","journal-title":"J Arthroplasty"},{"key":"6372_CR22","doi-asserted-by":"publisher","unstructured":"Emara AK, Pasqualini I, Jin Y, Klika AK, Orr MN, Rull\u00e1n PJ et al (2024) What Are the Diagnosis-Specific Thresholds of Minimal Clinically Important Difference and Patient Acceptable Symptom State in Hip Disability and Osteoarthritis Outcome Score After Primary Total Hip Arthroplasty? J Arthroplasty. https:\/\/doi.org\/10.1016\/j.arth.2024.01.051","DOI":"10.1016\/j.arth.2024.01.051"},{"issue":"3","key":"6372_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/1120700020947400","volume":"32","author":"JM Wilson","year":"2022","unstructured":"Wilson JM, Farley KX, Erens GA, Bradbury TL, Guild GN (2022) Preoperative opioid use is a risk factor for complication following revision total hip arthroplasty. Hip Int 32(3):363\u2013370. https:\/\/doi.org\/10.1177\/1120700020947400","journal-title":"Hip Int"},{"issue":"12","key":"6372_CR24","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1016\/j.arth.2017.08.010","volume":"32","author":"NA Bedard","year":"2017","unstructured":"Bedard NA, Pugely AJ, Dowdle SB, Duchman KR, Glass NA, Callaghan JJ (2017) Opioid Use Following Total Hip Arthroplasty: Trends and Risk Factors for Prolonged Use. J Arthroplasty 32(12):3675\u20133679. https:\/\/doi.org\/10.1016\/j.arth.2017.08.010","journal-title":"J Arthroplasty"},{"issue":"10","key":"6372_CR25","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1097\/CORR.0000000000001793","volume":"479","author":"TJ Rajam\u00e4ki","year":"2021","unstructured":"Rajam\u00e4ki TJ, Moilanen T, Puolakka PA, Hietaharju A, J\u00e4msen E (2021) Is the Preoperative Use of Antidepressants and Benzodiazepines Associated with Opioid and Other Analgesic Use After Hip and Knee Arthroplasty? Clin Orthop Relat Res 479(10):2268\u20132280. https:\/\/doi.org\/10.1097\/CORR.0000000000001793","journal-title":"Clin Orthop Relat Res"},{"issue":"2","key":"6372_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3928\/01477447-20210217-03","volume":"44","author":"V Singh","year":"2021","unstructured":"Singh V, Kugelman DN, Rozell JC, Meftah M, Schwarzkopf R, Davidovitch RI (2021) Impact of Preoperative Opioid Use on Patient Outcomes Following Primary Total Hip Arthroplasty. Orthopedics 44(2):77\u201384. https:\/\/doi.org\/10.3928\/01477447-20210217-03","journal-title":"Orthopedics"},{"issue":"9","key":"6372_CR27","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1111\/ans.17969","volume":"92","author":"P Huang","year":"2022","unstructured":"Huang P, Brownrigg J, Roe J, Carmody D, Pinczewski L, Gooden B et al (2022) Opioid use and patient outcomes in an Australian hip and knee arthroplasty cohort. ANZ J Surg 92(9):2261\u20132268. https:\/\/doi.org\/10.1111\/ans.17969","journal-title":"ANZ J Surg"},{"issue":"4","key":"6372_CR28","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.arth.2025.08.028","volume":"41","author":"AK Emara","year":"2026","unstructured":"Emara AK, Khan ST, Pasqualini I, Elmenawi KA, Zhang C, Gudapati LS et al (2026) Preoperative NarxCare Overdose Risk Scores Greater than 200 Are Associated With Worse 1-Year Patient-Reported Outcomes and Dissatisfaction after Primary Total Knee Arthroplasty. J Arthroplast 41(4):1100\u20131106e2. https:\/\/doi.org\/10.1016\/j.arth.2025.08.028","journal-title":"J Arthroplast"},{"issue":"7","key":"6372_CR29","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1016\/j.arth.2018.02.056","volume":"33","author":"PN Ramkumar","year":"2018","unstructured":"Ramkumar PN, Navarro SM, Haeberle HS, Ng M, Piuzzi NS, Spindler KP (2018) No Difference in Outcomes 12 and 24 Months After Lower Extremity Total Joint Arthroplasty: A Systematic Review and Meta-Analysis. J Arthroplasty 33(7):2322\u20132329. https:\/\/doi.org\/10.1016\/j.arth.2018.02.056","journal-title":"J Arthroplasty"},{"issue":"23","key":"6372_CR30","doi-asserted-by":"publisher","first-page":"01209","DOI":"10.1016\/j.arth.2023.12.017","volume":"S0883\u20135403","author":"I Pasqualini","year":"2023","unstructured":"Pasqualini I, Rull\u00e1n PJ, Huffman N, Klika AK, Shen J, Bhowmik-Stoker M et al (2023) Challenging the Status Quo: Debunking the Necessity of 5-Year to 10-Year Patient-Reported Outcome Measures in Total Hip and Knee Arthroplasties. J Arthroplasty S0883\u20135403(23):01209\u201301203. https:\/\/doi.org\/10.1016\/j.arth.2023.12.017","journal-title":"J Arthroplasty"},{"issue":"9","key":"6372_CR31","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00402-021-03819-x","volume":"142","author":"NS Piuzzi","year":"2022","unstructured":"Piuzzi NS, Cleveland Clinic OME, Arthroplasty Group (2022) Patient-reported outcomes at 1 and 2 years after total hip and knee arthroplasty: what is the minimum required follow-up? Arch Orthop Trauma Surg 142(9):2121\u20132129. https:\/\/doi.org\/10.1007\/s00402-021-03819-x","journal-title":"Arch Orthop Trauma Surg"},{"issue":"8S","key":"6372_CR32","doi-asserted-by":"publisher","first-page":"S716","DOI":"10.1016\/j.arth.2022.02.016","volume":"37","author":"A Seetharam","year":"2022","unstructured":"Seetharam A, Deckard ER, Ziemba-Davis M, Meneghini RM (2022) The AAHKS Clinical Research Award: Are Minimum Two-Year Patient-Reported Outcome Measures Necessary for Accurate Assessment of Patient Outcomes After Primary Total Knee Arthroplasty? J Arthroplasty 37(8S):S716\u2013S720. https:\/\/doi.org\/10.1016\/j.arth.2022.02.016","journal-title":"J Arthroplasty"}],"container-title":["Archives of Orthopaedic and Trauma Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00402-026-06372-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00402-026-06372-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00402-026-06372-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:34:01Z","timestamp":1781796841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00402-026-06372-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6372"],"URL":"https:\/\/doi.org\/10.1007\/s00402-026-06372-7","relation":{"references":[{"id-type":"doi","id":"10.2106\/JBJS.18.00767","asserted-by":"subject"},{"id-type":"doi","id":"10.1016\/j.arth.2018.07.011","asserted-by":"subject"}]},"ISSN":["1434-3916"],"issn-type":[{"value":"1434-3916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Nicolas Piuzzi reports consulting for Stryker, Pacira, and Zimmer; holding stock in Osteal Therapeutics; and receiving research support as a principal investigator from Osteal Therapeutics, Peptilogics, RegenLab, Signature Orthopedics, Zimmer, and Stryker. He also serves on the editorial board of The Journal of Bone and Joint Surgery and holds committee appointments with the American Association of Hip and Knee Surgeons and the Orthopaedic Research Society. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional Review Board approval was obtained prior to the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written consent was not obtained as the data source was a commercial de-identified national database.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Written consent"}},{"value":"Consent to published was not obtained as the data source was a commercial de-identified national database.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"223"}}